Inhibrx Biosciences (INBX) Enterprise Value (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Enterprise Value for 3 consecutive years, with -$153.1 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value rose 22.01% to -$153.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$153.1 million, a 22.01% increase, with the full-year FY2024 number at -$152.6 million, up 45.09% from a year prior.
- Enterprise Value was -$153.1 million for Q3 2025 at Inhibrx Biosciences, up from -$186.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$152.6 million in Q4 2024 to a low of -$277.9 million in Q4 2023.
- A 3-year average of -$201.4 million and a median of -$196.3 million in 2024 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: soared 45.09% in 2024, then increased 17.76% in 2025.
- Inhibrx Biosciences' Enterprise Value stood at -$277.9 million in 2023, then skyrocketed by 45.09% to -$152.6 million in 2024, then decreased by 0.32% to -$153.1 million in 2025.
- Per Business Quant, the three most recent readings for INBX's Enterprise Value are -$153.1 million (Q3 2025), -$186.6 million (Q2 2025), and -$216.5 million (Q1 2025).